Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent FDA leadership changes, including the resignation of Commissioner Marty Makary, Pfizer's financial metrics remain attractive with a non-GAAP P/E ratio of 8.6x and a 6.8% dividend yield. The company’s promising drug pipeline and steady sales growth support a 'Strong Buy' rating from analysts, indicating confidence in its future performance.
Pfizer reported that its obesity drug berobenatide achieved a 15.9% weight loss in a Phase 2b study without placebo adjustment. The pivotal Phase 3 trial for berobenatide is now open for enrollment, aiming to strengthen Pfizer's position in obesity t...
The alcohol use disorder (AUD) market is projected to expand at a 12.1% compound annual growth rate (CAGR) from 2026 to 2036, driven by unmet clinical needs and the development of novel therapies targeting new mechanisms like the 5-HT3 pathway and NO...
The Pacer US Cash Cows 100 ETF (COWZ), which invests in Russell 1000 companies with the highest free cash flow yields, is seeing its strategy tested as sectors like Energy and Pharma increase capital expenditures and payout ratios. Rising capex in En...
The 10th Annual New York CISO & Technology Leadership Summit, held on June 9, 2026, gathered top C-level tech leaders to discuss the evolving role of technology executives amid AI disruption and rising security demands. Key topics included leading li...
Pfizer reported positive mid-stage trial results for berobenatide, a potential first GLP-1 obesity therapy with monthly dosing, planning up to 10 Phase 3 trials this year. McDonald's is piloting ArchIQ, an AI-powered drive-thru system, automating 90%...
